title: Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.
abstract: OBJECTIVE
  To assess the incidence of the AIDS dementia complex and the presence of HIV I p24 antigen in cerebrospinal fluid in relation to zidovudine treatment.
  
  
  METHODS
  Retrospective study of a consecutive series of patients with AIDS from 1982 to 1988.
  
  
  METHODS
  An academic centre for AIDS.
  
  
  METHODS
  196 Patients with AIDS and neurological symptoms examined from 1982 to 1988.
  
  
  METHODS
  Zidovudine treatment, which was introduced to The Netherlands on 1 May 1987 for patients with severe symptoms of HIV infection (Centers for Disease Control groups IVA, B, C, and D).
  
  
  METHODS
  Diagnosis of AIDS dementia complex and presence of HIV I p24 antigen in cerebrospinal fluid.
  
  
  RESULTS
  The AIDS dementia complex was diagnosed in 40 of the 196 (20%) patients with AIDS. Thirty eight of 107 patients with AIDS (36%) not taking zidovudine developed the AIDS dementia complex compared with two of the 89 (2%) taking the drug (p less than 0.00001). The incidence of the AIDS dementia complex increased to 53% in the first half of 1987, after the introduction of zidovudine in May 1987, decreasing to 10% in the second half of 1987 and to 3% in 1988. Dementia was diagnosed before definition of the AIDS dementia complex (1986) according to DSM-III criteria and there was good agreement between diagnosis before and after 1986. Sixteen of 61 samples of cerebrospinal fluid (26%) from patients with AIDS (10 with the AIDS dementia complex) not taking zidovudine were positive for HIV I p24 antigen, whereas none of 37 cerebrospinal fluid samples from patients with AIDS (two with the AIDS dementia complex) taking zidovudine were positive.
  
  
  CONCLUSIONS
  The incidence of AIDS dementia complex in patients with AIDS declined after the introduction of systematic treatment with zidovudine; the AIDS dementia complex might be prevented by inhibiting viral replication in the central nervous system.
authors.affiliation: Academic Medical Centre, University of Amsterdam, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Portegies
authors.forename: J
authors.initials: J
authors.lastname: de Gans
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: M M
authors.initials: MM
authors.lastname: Derix
authors.forename: H
authors.initials: H
authors.lastname: Speelman
authors.forename: M
authors.initials: M
authors.lastname: Bakker
authors.forename: S A
authors.initials: SA
authors.lastname: Danner
authors.forename: J
authors.initials: J
authors.lastname: Goudsmit
mesh_terms: D015526:AIDS Dementia Complex / Q000134:cerebrospinal fluid / Q000453:epidemiology / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D003704:Dementia / Q000517:prevention & control; D015683:Gene Products, gag / Q000134:cerebrospinal fluid; D015488:HIV Antigens / Q000134:cerebrospinal fluid; D016655:HIV Core Protein p24; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D009426:Netherlands / Q000453:epidemiology; D012189:Retrospective Studies; D014758:Viral Core Proteins / Q000134:cerebrospinal fluid; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D015683:Gene Products, gag; D015488:HIV Antigens; D016655:HIV Core Protein p24; D014758:Viral Core Proteins; D015215:Zidovudine